Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant

Molecular Therapy

Volumn 21, Issue 11, 2013, Pages 2113-2121

  Gerdemann, Ulrike ^a   Katari, Usha L ^a   Papadopoulou, Anastasia ^a   Keirnan, Jacqueline M ^a   Craddock, John A ^a   Liu, Hao ^a   Martinez, Caridad A ^a   Kennedy Nasser, Alana ^a   Leung, Kathryn S ^a   Gottschalk, Stephen M ^a   Krance, Robert A ^a   Brenner, Malcolm K ^a   Rooney, Cliona M ^a   Heslop, Helen E ^a   Leen, Ann M ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; CYTOMEGALOVIRUS ANTIBODY; FOSCARNET; GANCICLOVIR; RITUXIMAB; VIRUS ANTIGEN;

ADENOVIRUS INFECTION; ADOLESCENT; ADOPTIVE TRANSFER; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL ACTIVITY; ARTICLE; BK VIRUS INFECTION; CELL EXPANSION; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DONOR; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IN VIVO STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; RASH; SAFETY; SCHOOL CHILD; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; VIROLOGY; VIRUS LOAD;

ADENOVIRIDAE; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 4;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ADOLESCENT; ADOPTIVE TRANSFER; ANTIGENS, VIRAL; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA VIRUSES; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; MALE; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 84887501471     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.151     Document Type: Article

References (42)

1. Schonberger, S, Meisel, R, Adams, O, Pufal, Y, Laws, HJ, Enczmann, J et al. (2010). Prospective, comprehensive and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation. Biol.Blood Marrow Transplant 16: 1428-1435.
2. Verdeguer, A, de Heredia, CD, González, M, Martínez, AM, Fernández-Navarro, JM, Pérez-Hurtado, JM et al.; GETMON: Spanish Working Party for Blood and Marrow Transplantation in Children. (2011). Observational prospective study of viral infections in children undergoing allogeneic hematopoietic cell transplantation: a 3-year GETMON experience. Bone Marrow Transplant 46: 119-124.
3. Leen, AM, Myers, GD, Sili, U, Huls, MH, Weiss, H, Leung, KS et al. (2006). Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12: 1160-1166.
4. Sili, U, Leen, AM, Vera, JF, Gee, AP, Huls, H, Heslop, HE et al. (2012). Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections postallogeneic hematopoietic stem cell transplant. Cytotherapy 14: 7-11.
5. Leen, AM, Christin, A, Khalil, M, Weiss, H, Gee, AP, Brenner, MK et al. (2008). Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 82: 546-554.
6. Gerdemann, U, Christin, AS, Vera, JF, Ramos, CA, Fujita, Y, Liu, H et al. (2009). Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther 17: 1616-1625.
7. Gerdemann, U, Keirnan, JM, Katari, UL, Yanagisawa, R, Christin, AS, Huye, LE et al. (2012). Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther 20: 1622-1632.
8. Gerdemann, U, Vera, JF, Rooney, CM and Leen, AM (2011). Generation of multivirusspecific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant. J Vis Exp.
9. Melenhorst, JJ, Leen, AM, Bollard, CM, Quigley, MF, Price, DA, Rooney, CM et al. (2010). Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 116: 4700-4702.
10. Wagner, HJ, Cheng, YC, Huls, MH, Gee, AP, Kuehnle, I, Krance, RA et al. (2004). Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 103: 3979-3981.
11. Gottschalk, S, Ng, CY, Perez, M, Smith, CA, Sample, C, Brenner, MK et al. (2001). An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 97: 835-843.
12. Riker, A, Cormier, J, Panelli, M, Kammula, U, Wang, E, Abati, A et al. (1999). Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126: 112-120.
13. Leen, AM, Christin, A, Myers, GD, Liu, H, Cruz, CR, Hanley, PJ et al. (2009). Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 114: 4283-4292.
14. Feuchtinger, T, Opherk, K, Bethge, WA, Topp, MS, Schuster, FR, Weissinger, EM et al. (2010). Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116: 4360-4367.
15. Feuchtinger, T, Matthes-Martin, S, Richard, C, Lion, T, Fuhrer, M, Hamprecht, K et al. (2006). Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 134: 64-76.
16. Micklethwaite, K, Hansen, A, Foster, A, Snape, E, Antonenas, V, Sartor, M et al. (2007). Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 13: 707-714.
17. Bunde, T, Kirchner, A, Hoffmeister, B, Habedank, D, Hetzer, R, Cherepnev, G et al. (2005). Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201: 1031-1036.
18. Walter, EA, Greenberg, PD, Gilbert, MJ, Finch, RJ, Watanabe, KS, Thomas, ED et al. (1995). Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333: 1038-1044.
19. Cobbold, M, Khan, N, Pourgheysari, B, Tauro, S, McDonald, D, Osman, H et al. (2005). Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 202: 379-386.
20. Peggs, KS, Verfuerth, S, Pizzey, A, Khan, N, Guiver, M, Moss, PA et al. (2003). Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362: 1375-1377.
21. Zandvliet, ML, Falkenburg, JH, van Liempt, E, Veltrop-Duits, LA, Lankester, AC, Kalpoe, JS et al. (2010). Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection. Haematologica 95: 1943-1951.
22. Heslop, HE, Slobod, KS, Pule, MA, Hale, GA, Rousseau, A, Smith, CA et al. (2010). Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115: 925-935.
23. Heslop, HE, Ng, CY, Li, C, Smith, CA, Loftin, SK, Krance, RA et al. (1996). Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2: 551-555.
24. Rooney, CM, Smith, CA, Ng, CY, Loftin, S, Li, C, Krance, RA et al. (1995). Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345: 9-13.
25. Icheva, V, Kayser, S, Wolff, D, Tuve, S, Kyzirakos, C, Bethge, W et al. (2013). Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 31: 39-48.
26. Moosmann, A, Bigalke, I, Tischer, J, Schirrmann, L, Kasten, J, Tippmer, S et al. (2010). Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 115: 2960-2970.
27. Hislop, AD, Taylor, GS, Sauce, D and Rickinson, AB (2007). Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25: 587-617.
28. Amir, AL, D'Orsogna, LJ, Roelen, DL, van Loenen, MM, Hagedoorn, RS, de Boer, R et al. (2010). Allo-HLA reactivity of virus-specific memory T cells is common. Blood 115: 3146-3157.
29. Amir, AL, Hagedoorn, RS, van Luxemburg-Heijs, SA, Marijt, EW, Kruisselbrink, AB, Frederik Falkenburg, JH et al. (2012). Identification of a coordinated CD8 and CD4 T cell response directed against mismatched HLA Class I causing severe acute graftversus-host disease. Biol Blood Marrow Transplant 18: 210-219.
30. D'Orsogna, LJ, Amir, AL, Zoet, YM, van der Meer-Prins, PM, van der Slik, AR, Kester, MG et al. (2009). New tools to monitor the impact of viral infection on the alloreactive T-cell repertoire. Tissue Antigens 74: 290-297.
31. Rist, M, Smith, C, Bell, MJ, Burrows, SR and Khanna, R (2009). Cross-recognition of HLA DR4 alloantigen by virus-specific CD8+ T cells: a new paradigm for self-/nonselfrecognition. Blood 114: 2244-2253.
32. Burrows, SR, Silins, SL, Moss, DJ, Khanna, R, Misko, IS and Argaet, VP (1995). T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J Exp Med 182: 1703-1715.
33. Burrows, SR, Silins, SL, Khanna, R, Burrows, JM, Rischmueller, M, McCluskey, J et al. (1997). Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. Eur J Immunol 27: 1726-1736.
34. Burrows, SR, Khanna, R, Burrows, JM and Moss, DJ (1994). An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med 179: 1155-1161.
35. Doubrovina, E, Oflaz-Sozmen, B, Prockop, SE, Kernan, NA, Abramson, S, Teruya-Feldstein, J et al. (2012). Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 119: 2644-2656.
36. Barker, JN, Doubrovina, E, Sauter, C, Jaroscak, JJ, Perales, MA, Doubrovin, M et al. (2010). Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 116: 5045-5049.
37. Haque, T, Wilkie, GM, Taylor, C, Amlot, PL, Murad, P, Iley, A et al. (2002). Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360: 436-442.
38. Haque, T, Wilkie, GM, Jones, MM, Higgins, CD, Urquhart, G, Wingate, P et al. (2007). Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110: 1123-1131.
39. Mifsud, NA, Nguyen, TH, Tait, BD and Kotsimbos, TC (2010). Quantitative and functional diversity of cross-reactive EBV-specific CD8+ T cells in a longitudinal study cohort of lung transplant recipients. Transplantation 90: 1439-1449.
40. Luke, J, Carnes, AE, Hodgson, CP and Williams, JA (2009). Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system. Vaccine 27: 6454-6459.
41. Luke, JM, Vincent, JM, Du, SX, Gerdemann, U, Leen, AM, Whalen, RG et al. (2011). Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers. Gene Ther 18: 334-343.
42. Vera, JF, Brenner, LJ, Gerdemann, U, Ngo, MC, Sili, U, Liu, H et al. (2010). Accelerated production of antigen-specific T cells for preclinical and clinical applications using gaspermeable rapid expansion cultureware (G-Rex). J Immunother 33: 305-315.